Novel strategy to identify MHC class II-promiscuous CD4+ peptides from tumor antigens for utilization in vaccination

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

patent: 5 patents

Readers on

mendeley: 1 Mendeley

So far, Altmetric has seen 5 patents that reference this research output.

IDENTIFICATION OF IMMUNOGENIC MHC CLASS II PEPTIDES FOR IMMUNE-BASED THERAPY

Application US-20210163573-A1

United States of America

03 Jun 2021

IDENTIFICATION OF IMMUNOGENIC MHC CLASS II PEPTIDES FOR IMMUNE-BASED THERAPY

Application EP-3791891-A1

European Patent Office

17 Mar 2021

Identification of immunogenic MHC class II peptides for immune-based therapy

Grant US-10829538-B2

United States of America

10 Nov 2020

IDENTIFICATION OF IMMUNOGENIC MHC CLASS II PEPTIDES FOR IMMUNE-BASED THERAPY

Application EP-3169354-A4

European Patent Office

13 Jun 2018

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 1 additional patents.